Drug Database
Back to search

Belgium· BE-AMP-SAM661618-00

Briumvi 150 mg

A ublituximab product containing ublituximab, registered in Belgium by Neuraxpharm Pharmaceuticals. The same ATC class is registered in 12 of our 19 countries.

ATC L04AG14

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedBriumvi 150 mgATCL04AG14REGISTER NO.BE-AMP-SAM661618-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ublituximabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ublituximab is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AG14 (ublituximab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose
Search ublituximab products by name

Ublituximab · ATC L04AG14

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Ublituximab
Manufacturer
Neuraxpharm Pharmaceuticals
Country
Belgium (BE)
ATC code
L04AG14
ATC class
Ublituximab
Defined daily dose
2.68 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    4901724
  • be_apb
    7742877

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Ublituximab in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ublituximab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Briumvi
  • Liechtenstein · Briumvi
  • Norway · Briumvi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4ff5d3f2-6285-45d2-9403-0f99cc4c835f
GET /v1/drugs/4ff5d3f2-6285-45d2-9403-0f99cc4c835f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Briumvi 150 mg",
  "name_fr": "Briumvi 150 mg",
  "name_nl": "Briumvi 150 mg",
  "amp_code": "SAM661618-00",
  "strengths": [
    "25.0000",
    "25.0000",
    "25.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Ublituximab",
    "Sodium Chloride",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Ublituximab",
  "authorisation_numbers": [
    "EU/1/23/1730/001",
    "EU/1/23/1730/002"
  ]
}
API referenceMCP serverPlans

See everything about ublituximab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console